Clinical Trials Logo
  1. Home
  2. Other
  3. NCT01150669

Lestaurtinib With or Without Chemotherapy Agents in Samples From Young Patients With Leukemia

Childhood Acute Lymphoblastic Leukemia Clinical Trial

Official title:
SCOR in Targeted Therapies for Infant Leukemia Project 3: Targeting FLT3 in Infant Leukemia

Clinical Trial Summary

This research study is studying lestaurtinib with or with chemotherapy in samples from young patients with leukemia. Studying the effects of lestaurtinib with or without chemotherapy in cell samples from patients with cancer in the laboratory may help doctors learn more about the effects of this treatment on cancer cells. It may also help doctors identify biomarkers related to cancer.

Clinical Trial Description

PRIMARY OBJECTIVES:

I. Determine the potential of lestaurtinib with or without chemotherapy agents in treating samples from infants with leukemia.

II. Determine whether FLT3 protein expression level and/or activation and sensitivity to lestaurtinib differ between subgroups of infants with leukemia.

III. Determine whether lestaurtinib activates STAT5, AKT, and RAS-MAPK and other pathways.

IV. Determine whether lestaurtinib can synergize with other chemotherapy agents kill infant leukemia cells.

OUTLINE: This is a multicenter study.

Cryopreserved specimens are studied in vitro with lestaurtinib with or without chemotherapy agents. Samples are analyzed for FLT3 protein expression and/or activation; sensitivity to lestaurtinib with or without chemotherapy agents; and activation of STAT, AKT, and RAS-MAPK and other pathways by western blot. The most effective treatment from this study is then validated in vivo in a NOD/SCID xenograft model. ;

Study Design

Observational Model: Case-Only, Time Perspective: Retrospective

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT01150669
Study type Observational
Source Children's Oncology Group
Contact
Status Completed
Phase N/A
Start date July 2010
Completion date May 2016
View Details
See also
  Status Clinical Trial Phase
Active, not recruiting NCT04541056 - Goal Management Training for Adult Survivors of Childhood Leukemia and Non-Hodgkins Lymphoma With Neurocognitive Sequelae N/A
Recruiting NCT01990807 - Treatment Protocol of Children With Philadelphia Chromosome Negative High Risk Acute Lymphoblastic Leukemia Phase 4
Completed NCT00898079 - Collecting and Storing Malignant, Borderline Malignant Neoplasms, and Related Samples From Young Patients With Cancer
Recruiting NCT03390387 - Childhood Acute Lymphoblastic Leukemia Treatment Protocol Moscow-Berlin 2015 (ALL-MB 2015) N/A
Withdrawn NCT01492569 - Acupuncture Point Stimulation for Treatment of Chemotherapy Nausea and Vomiting N/A
Recruiting NCT05452668 - Laser Therapy Effect on Oral Mucositis in Childhood Acute Lymphoblastic Leukemia Patients N/A
Recruiting NCT05729178 - Unravelling the Role of KCTD Protein Family in the Clinical Management of Childhood Acute Lymphoblastic Leukemias
Recruiting NCT03981510 - Comparison of Gastrointestinal Motility in Healthy Children and Children With Constipation N/A
Active, not recruiting NCT01953770 - Childhood Acute Lymphoblastic Leukemia Treatment Protocol Moscow-Berlin 2008 N/A
Completed NCT00674193 - Evaluating Dactinomycin and Vincristine in Young Patients With Cancer N/A
Completed NCT00537030 - Erwinia Asparaginase After Allergy to PEG-Asparaginase in Treating Young Patients With Acute Lymphoblastic Leukemia N/A
Recruiting NCT04723342 - Acute Lymphoblastic Leukemia Treatment Protocol Moscow-Berlin 2019 Pilot N/A
Completed NCT01251575 - Sirolimus, Cyclosporine, and Mycophenolate Mofetil in Preventing Graft-versus-Host Disease in Treating Patients With Blood Cancer Undergoing Donor Peripheral Blood Stem Cell Transplant Phase 2
Recruiting NCT04626765 - CAR-T for Children With Relapsed and Refractory Acute Lymphoblastic Leukemia Early Phase 1